Results 171 to 180 of about 5,054 (206)
Dermatologic Therapy, 2022 20.500.12530/87870NAVIGATE clinical trial demonstrated a higher rate of Psoriasis Assesment Severity Index (PASI)90 response in patients treated with guselkumab when compared to ustekinumab and an improved response in those who switched from ustekinumab ...
Mar Llamas-Velasco, Raquel Rivera
exaly +2 more sources
Dermatologic Therapy, 2022 IL‐23‐inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness,
Angelo Ruggiero +2 more
exaly +2 more sources
Nummular dermatitis on guselkumab for palmoplantar psoriasis [PDF]
Dermatologic Therapy, 2019 A 40-year-old man with chronic history of refractory palmoplantar psoriasis presented with new onset of well-demarcated oval erythematous asteatotic plaques on bilateral shins after starting guselkumab therapy.
Stephanie Le +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Canadian Journal of Health Technologies, 2022
CADTH recommends that Tremfya be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met. Tremfya should only be reimbursed to treat adult patients with active PsA according to the reimbursement criteria used for other biologic disease-modifying antirheumatic drugs (DMARDs) that ...
openaire +1 more source
CADTH recommends that Tremfya be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met. Tremfya should only be reimbursed to treat adult patients with active PsA according to the reimbursement criteria used for other biologic disease-modifying antirheumatic drugs (DMARDs) that ...
openaire +1 more source
Guselkumab in Behçet's disease
Annals of the Rheumatic DiseasesN ...
Elie E Ghayad +14 more
openaire +3 more sources
Guselkumab: First Global Approval
Drugs, 2017Guselkumab (Tremfya™) is a human monoclonal IgG1λ antibody being developed by Janssen Biotech, Inc. that has been approved in the USA as a treatment for moderate-to-severe plaque psoriasis. Guselkumab inhibits the binding of interleukin 23 (IL-23) to its cell surface receptor, disrupting the type 17 helper T cell/IL-17 pathway.
openaire +2 more sources